NASDAQ:GMAB

Genmab A/S (GMAB) Stock Price, News & Analysis

$29.98
+0.33 (+1.11%)
(As of 05/17/2024 ET)
Today's Range
$29.52
$30.00
50-Day Range
$27.46
$31.68
52-Week Range
$26.32
$42.72
Volume
375,160 shs
Average Volume
555,330 shs
Market Capitalization
$19.82 billion
P/E Ratio
24.98
Dividend Yield
N/A
Price Target
$48.50

Genmab A/S MarketRank™ Stock Analysis

Analyst Rating
Hold
2.38 Rating Score
Upside/​Downside
61.8% Upside
$48.50 Price Target
Short Interest
Bearish
0.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.87mentions of Genmab A/S in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
26.13%
From $1.11 to $1.40 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.97 out of 5 stars

Medical Sector

382nd out of 921 stocks

Pharmaceutical Preparations Industry

166th out of 419 stocks

GMAB stock logo

About Genmab A/S Stock (NASDAQ:GMAB)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

GMAB Stock Price History

GMAB Stock News Headlines

Genmab: A Complicated Tale
Genmab A/S (GMAB)
See More Headlines
Receive GMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
5/18/2024
Next Earnings (Estimated)
8/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GMAB
Fax
N/A
Employees
2,204
Year Founded
1999

Price Target and Rating

Average Stock Price Target
$48.50
High Stock Price Target
$50.00
Low Stock Price Target
$46.00
Potential Upside/Downside
+61.8%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
13 Analysts

Profitability

Net Income
$631.91 million
Pretax Margin
39.74%

Debt

Sales & Book Value

Annual Sales
$2.39 billion
Cash Flow
$1.25 per share
Book Value
$7.16 per share

Miscellaneous

Free Float
651,047,000
Market Cap
$19.82 billion
Optionable
Optionable
Beta
1.00

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Jan G.J. van de Winkel Ph.D. (Age 63)
    Co-Founder, President & CEO
    Comp: $2.85M
  • Mr. Anthony Pagano (Age 46)
    Executive VP & CFO
    Comp: $1.01M
  • Ms. Birgitte Stephensen M.Sc. (Age 63)
    Executive VP & Chief Legal Officer
    Comp: $627.66k
  • Dr. Martine J. van Vugt Ph.D. (Age 53)
    Executive VP & Chief Strategy Officer
    Comp: $684.72k
  • Mr. Martin Schultz (Age 48)
    Senior Director of Clinical Operations & Non-Independent Director
    Comp: $114.12k
  • Dr. Tahamtan Ahmadi (Age 51)
    Executive VP, Chief Medical Officer & Head of Experimental Medicines
    Comp: $1.1M
  • Dr. Mijke Zachariasse Ph.D. (Age 50)
    Senior Director, Head of Antibody Research Materials & Non-Independent Director
    Comp: $156.91k
  • Mr. Takahiro Hamatani (Age 49)
    Senior Director of Finance Japan & Non-Independent Director
    Comp: $114.12k
  • Mr. Anthony Mancini (Age 53)
    Executive VP & COO
    Comp: $1.08M
  • Mr. Andrew Carlsen
    Senior Director, VP & Head of Investor Relations

GMAB Stock Analysis - Frequently Asked Questions

Should I buy or sell Genmab A/S stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last twelve months. There are currently 3 sell ratings, 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GMAB, but not buy additional shares or sell existing shares.
View GMAB analyst ratings
or view top-rated stocks.

What is Genmab A/S's stock price target for 2024?

13 brokerages have issued 12 month price targets for Genmab A/S's stock. Their GMAB share price targets range from $46.00 to $50.00. On average, they anticipate the company's share price to reach $48.50 in the next twelve months. This suggests a possible upside of 61.8% from the stock's current price.
View analysts price targets for GMAB
or view top-rated stocks among Wall Street analysts.

How have GMAB shares performed in 2024?

Genmab A/S's stock was trading at $31.84 at the beginning of 2024. Since then, GMAB stock has decreased by 5.8% and is now trading at $29.98.
View the best growth stocks for 2024 here
.

When is Genmab A/S's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our GMAB earnings forecast
.

How were Genmab A/S's earnings last quarter?

Genmab A/S (NASDAQ:GMAB) issued its earnings results on Wednesday, November, 10th. The company reported $0.21 EPS for the quarter, topping the consensus estimate of $0.11 by $0.10. The business had revenue of $366.25 million for the quarter, compared to analysts' expectations of $341.46 million. Genmab A/S had a trailing twelve-month return on equity of 18.90% and a net margin of 30.74%. During the same period in the prior year, the firm earned $0.13 EPS.

What guidance has Genmab A/S issued on next quarter's earnings?

Genmab A/S issued an update on its FY 2024 earnings guidance on Friday, May, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.7 billion-$3.0 billion, compared to the consensus revenue estimate of $2.8 billion.

What other stocks do shareholders of Genmab A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genmab A/S investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), CVS Health (CVS), Home Depot (HD), Intel (INTC), Pfizer (PFE), PayPal (PYPL), Verizon Communications (VZ) and Cisco Systems (CSCO).

When did Genmab A/S IPO?

Genmab A/S (GMAB) raised $503 million in an IPO on Thursday, July 18th 2019. The company issued 27,800,000 shares at $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers.

Who are Genmab A/S's major shareholders?

Genmab A/S's stock is owned by a variety of institutional and retail investors. Top institutional investors include Capital International Investors (0.66%), Oppenheimer Asset Management Inc. (0.03%), Raymond James & Associates (0.03%), US Bancorp DE (0.02%), Williams Jones Wealth Management LLC. (0.01%) and Bamco Inc. NY (0.01%).

How do I buy shares of Genmab A/S?

Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GMAB) was last updated on 5/19/2024 by MarketBeat.com Staff

From Our Partners